V3640

Valpromide

≥97% (NMR)

• Sinónimos: 2-Propylvaleramide, 2-propyl-pentanamide, Depamid, Depamide, Di-n-propylacetamide, Dipropylacetamide
• Fórmula empírica (notación de Hill): C₈H₁₇NO
• Número CAS: 2430-27-5
• Peso molecular: 143.23
• NACRES: NA.77
• PubChem Substance ID: 329829044
• UNSPSC Code: 12352200
• MDL number: MFCD00051534
• Assay: ≥97% (NMR)
• Form: powder

Propiedades

• Quality Segment: 100
• assay: ≥97% (NMR)
• form: powder
• color: white to off-white
• solubility: DMSO: >10 mg/mL
• originator: Sanofi Aventis
• storage temp.: room temp
• SMILES string: CCCC(CCC)C(N)=O
• InChI: 1S/C8H17NO/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H2,9,10)
• InChI key: OMOMUFTZPTXCHP-UHFFFAOYSA-N

Descripción

Application

Valpromide has been used to pretreat NIH/3T3 cells to test its effect on cytomegalovirus (CMV) viral replication.[1] It has also been used to test its antiviral functionality in herpes simplex virus type 1 (HSV-1) infected human oligodendroglioma (HOG) cells.[2] It may be used to test its effect on apoptosis induction in astrocytes.

Biochem/physiol Actions

Valpromide (VPD) is a derivative of valproic acid (VPA) and is used as an antiepileptic drug.

Valpromide (VPD) is a derivative of valproic acid (VPA) and is used as an antiepileptic drug. It is hydrolyzed quickly to VPA in vivo, but has intrinsic anticonvulsant activity.

Valpromide possesses antipsychotic property. It lacks the toxic and teratogenic effects of valproic acid.[2] It also lacks the histone deacetylase (HDAC) inhibitory activity of valproic acid.[2]

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• pictograms: GHS07
• signalword: Warning
• hcodes: H302
• pcodes: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable